Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report

Neoadjuvant targeted therapy is an alternative treatment for locally advanced non-small cell lung cancer (NSCLC) patients with driver gene mutation. MET ex14 mutation is considered a driver gene, and crizotinib is the first oral tyrosine kinase inhibitor (TKI) for metastatic MET ex14 mutation-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiantao, Yao, Wenqing, Wang, Weiya, Fan, Mingyu, Huang, Kaili, Liu, Zhenkun, Zhu, Daxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405726/
https://www.ncbi.nlm.nih.gov/pubmed/37554169
http://dx.doi.org/10.3389/fonc.2023.1164543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405726/
https://www.ncbi.nlm.nih.gov/pubmed/37554169
http://dx.doi.org/10.3389/fonc.2023.1164543

Ejemplares similares